Browse by author
Lookup NU author(s): Professor Linda Sharp
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).
© 2017 Cancer Research UK. Background:Increasing incidence and new indications for existing drugs make it important to identify new adjuvant therapies for endometrial cancer (EC).Methods:This is a prospective cohort study of 3058 newly diagnosed EC cases from 1998 to 2010, identified through record linkages between the UK Clinical Practice Research Datalink, the National Cancer Research Datalink and death registrations from the Office of National Statistics. Using Cox regression models, unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for EC-specific survival.Results:Over a mean 6.1 (range 1-16) years of follow-up, there were 394 EC-specific deaths. There was no evidence of a significant association between post-diagnostic use of statins (adjusted HR 0.83, 95% CI 0.64, 1.08), β-blockers (adjusted HR 0.86, 95% CI 0.65, 1.13) or low-dose aspirin (adjusted HR 0.91, 95% CI 0.69, 1.20) and EC survival before or after adjustment for confounders. There were also no evidence of a dose-response association between these drug groups and EC survival.Conclusions:In this large UK population-based study, no significant associations were observed for post-diagnostic use of statins, β-blockers or low-dose aspirin and EC survival.
Author(s): Sanni OB, Mc Menamin UC, Cardwell CR, Sharp L, Murray LJ, Coleman HG
Publication type: Article
Publication status: Published
Journal: British Journal of Cancer
Year: 2017
Volume: 117
Issue: 3
Pages: 432-438
Print publication date: 25/07/2017
Online publication date: 06/07/2017
Acceptance date: 09/06/2017
Date deposited: 27/01/2021
ISSN (print): 0007-0920
ISSN (electronic): 1532-1827
Publisher: Nature Publishing Group
URL: https://doi.org/10.1038/bjc.2017.207
DOI: 10.1038/bjc.2017.207
PubMed id: 28683466
Altmetrics provided by Altmetric
